{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV+Associated+Cancer",
    "query": {
      "condition": "HPV Associated Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV+Associated+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T20:45:21.671Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05307939",
      "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV",
        "Oropharynx Cancer",
        "HPV-Related Carcinoma",
        "HPV-Related Malignancy",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HPV ctDNA Assay",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI Studies",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "EORTC QLQ H&N 35 and C30",
          "type": "BEHAVIORAL"
        },
        {
          "name": "MDADI-HN",
          "type": "BEHAVIORAL"
        },
        {
          "name": "COST-FACIT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy (Arm A)",
          "type": "RADIATION"
        },
        {
          "name": "Chemoradiation (Arm B)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL",
        "RADIATION",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-24",
      "completion_date": "2027-03-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307939"
    },
    {
      "nct_id": "NCT05317000",
      "title": "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Combination 5-azacytidine and nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Burtness",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-03-23",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317000"
    },
    {
      "nct_id": "NCT01084083",
      "title": "Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Precancerous Condition"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "intensity-modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2010-08-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01084083"
    },
    {
      "nct_id": "NCT04369937",
      "title": "HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IMRT (Intensity Modulated Radiotherapy)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "ISA101b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-07-06",
      "completion_date": "2026-03-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04369937"
    },
    {
      "nct_id": "NCT05996523",
      "title": "Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oropharyngeal Squamous Cell Carcinoma (SCC)"
      ],
      "interventions": [
        {
          "name": "PRGN-2009",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PET scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-11-07",
      "completion_date": "2030-07-16",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05996523"
    },
    {
      "nct_id": "NCT04900623",
      "title": "Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV-Associated Oropharyngeal Squamous Cell Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage",
        "HPV-Related Squamous Cell Carcinoma",
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage",
        "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage"
      ],
      "interventions": [
        {
          "name": "NavDx HPV ctDNA Testing",
          "type": "DEVICE"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Chemotherapy drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Jonathan Schoenfeld, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2021-07-02",
      "completion_date": "2032-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900623"
    },
    {
      "nct_id": "NCT06309225",
      "title": "Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oropharynx Cancer",
        "Frailty"
      ],
      "interventions": [
        {
          "name": "Modified dose and fields intensity modulated radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Omar Mahmoud",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "65 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-05-15",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06309225"
    },
    {
      "nct_id": "NCT04667585",
      "title": "Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oropharynx Cancer"
      ],
      "interventions": [
        {
          "name": "De-escalated radiation dose",
          "type": "RADIATION"
        },
        {
          "name": "Standard radiation dose",
          "type": "RADIATION"
        },
        {
          "name": "18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2021-04-12",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04667585"
    },
    {
      "nct_id": "NCT00005941",
      "title": "Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Vaginal Cancer"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "Up to 64 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "1999-11",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005941"
    },
    {
      "nct_id": "NCT05985681",
      "title": "Testing RG1-VLP Vaccine to Prevent HPV-related Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "HPV16 RG1 VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2026-01-27",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-07-23T20:45:21.671Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Staten Island, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Staten Island",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05985681"
    }
  ]
}